Skip to main content

The BioCommerce Week Index: Mar 17, 2005

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(March 15, 2005)
Last Price
(
March 8, 2005)
% Change
Agilent
A
23.26
24.36
-4.52
Applied Biosystems
ABI
20.34
20.69
-1.69
BD
BDX
58.85
58.85
0.00
Beckman
BEC
70.78
69.88
1.29
Bio-Rad
BIO
47.83
48.51
-1.40
Bruker
BRKR
3.95
3.78
4.50
GE
GE
36.00
36.06
-0.17
Harvard Bio
HBIO
3.95
4.43
-10.84
Invitrogen
IVGN
71.40
71.66
-0.36
Molecular Devices
MDCC
18.76
20.05
-6.43
PerkinElmer
PKI
21.90
23.01
-4.82
Sigma
SIAL
63.00
63.79
-1.24
Stratagene
STGN
8.00
7.39
8.25
Thermo
TMO
27.45
27.69
-0.87
Waters
WAT
47.85
49.32
-2.98
Index Average
34.89
35.30
-1.16

 

Stratagene Gains 8 Percent as Index Falls a Fraction

After charting better than 13 percent growth in the six months from Sept. 8, 2004, shares of the 15 companies listed in the BioCommerce Week Index fell just over 1 percent over the five-day period ending Tuesday.

Stratagene's stock gained 8.25 percent on the week after the company unveiled its molecular diagnostics strategy following last week's release of its fourth quarter financials (see article).

Shares of Bruker Bioscience improved better than 4 percent on the week as three BCW Index companies' shares finished up.

Harvard Bioscience, coming off a year of dealing with its underperforming Genomic Solutions, dropped 11 percent on the week, after losing 4 percent over the previous six months (see article).

Closing at $35.30 on Tuesday, the index was down 1.16 percent for the week, but still outperformed the Dow, which was down 1.2 percent; the S&P 500, which was down 1.6 percent; and the Nasdaq index, which finished the week down approximately 1.7 percent.

The Amex biotech index moved up 2 percent on the week on Genentech's news that its Avastin oncology drug helped prolong life in lung cancer patients in clinical trials, while the Amex pharma index fell 1.5 percent.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.